Blood-Brain Barrier and Neuro-Oncology Program


Collaborative Opportunities with the Blood-Brain Barrier Consortium for Diagnostic and Therapeutic Clinical Trials

The Oregon Health & Science University (OHSU) Blood-Brain Barrier (BBB) and Neuro-Oncology Program is pleased to present an ancillary session during the Society for Neuro-Oncology Annual Meeting titled “Collaborative Opportunities with the Blood-Brain Barrier Consortium for Diagnostic and Therapeutic Clinical Trials.” This session will present information on current and potential opportunities for collaboration on ongoing multicenter diagnostic and therapeutic clinical trials led by the BBB Consortium.

Discussion will be led by study investigators and include presentations on steady state neuroimaging, immunotherapy for brain tumors, antibody drug conjugate drug therapy, maintenance immunotherapy for primary central nervous system lymphoma, and the use of thiols for hearing protection particularly in pediatric patients with medulloblastoma.

This unique opportunity provides a stellar platform for increased exposure of these multicenter trials, as well as potential for input and participation from leaders in the field of neuro-oncology.

Registration and dinner are complimentary. Individuals who are not registered for the SNO Annual Meeting are welcome to attend; however, SNO registration is required to attend other sessions.

For more information, visit www.ohsu.edu/bbbmidannual or contact Emily Youngers at hochhalt@ohsu.edu or 503-494-5696.

Group(s): AANS CNS

When?

Fri, Nov. 17, 2017
5:30 p.m. - 7:30 p.m.
(GMT-0800) US/Pacific

Where?

San Francisco Marriott Marquis
780 Mission St
San Francisco, CA 94103

Foothill C